On December 28, 2021, the FDA updated the emergency use authorization (EUA) for COVID-19 convalescent plasma. The update limits the authorization to the use of COVID-19 convalescent plasma with high titers of anti -SARS-CoV-2 antibodies for the treatment of COVID-19 in patients with immunosuppressive disease or who are receiving immunosuppressive treatment. Additionally, to help assure the manufacture of high titer COVID-19 convalescent plasma, the revisions to the EUA define acceptable tests and increase qualifying result cutoffs to be used for manufacturing COVID-19 convalescent plasma with high titers of anti-SARS-CoV-2 antibodies.
We are currently evaluating our options to determine if we can provide additional testing services using one of the newly defined assays. Please reach out to your customer service manager if your organization is considering CCP testing under the updated guidelines.
As previously mentioned in Zika communications distributed on September 21 and October 12, 2018; ord...
We received an updated WNV package insert; please note the manufacturer and license number has been ...
CTS Tampa has implemented the Ortho Vitros Anti-SARS-CoV-2 Total test which qualitatively detects an...
A new Learning Center website will launch on Monday, March 30, 2020. While the link to the new Learn...
Currently, there are limited supplies of the reagents used for HIV-1 Western Blot and HIV-2 EIA test...
We sincerely hope to see you at this year’s AABB Annual Meeting in Boston, MA on October 12-16...